Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
A team of researchers from NYU Abu Dhabi and the University of Denver has identified a promising small molecule that could help slow or halt the progression of serious brain diseases such as Parkinson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results